Table 1– Clinical outcomes and sputum cell counts after azithromycin treatment or placebo
VariablesBaseline4 weeksTreatment difference#, azithromycin minus placebo (95%CI)8 weeksTreatment difference#, azithromycin minus placebo (95%CI)12 weeksTreatment difference#, azithromycin minus placebo (95%CI)
PlaceboAzithromycinPlaceboAzithromycinPlaceboAzithromycinPlaceboAzithromycin
Morning clinic PEF L·min−1411.1±124.3390.5±114.5412.9±110.6384.2±143.5-4.2 (-30.6–22.2), p=0.75406.0±120.4394.6±150.71.2 (-28.1–30.5), p=0.94416.7±122.7394.2±156.3-10.3 (-47.1–26.4), p=0.58
FEV1 pre-albuterol L2.54±0.772.43±0.722.48±0.742.37±0.760.08 (-0.06–0.23), p=0.252.47±0.772.42±0.750.03 (-0.08–0.14), p=0.552.46±0.752.41±0.770.03 (-0.08–0.14), p=0.62
FEV1 post-albuterol L2.80±0.802.68±0.732.73±0.722.59±0.740.04 (-0.08–0.17), p=0.502.72±0.802.68±0.740.04 (-0.04–0.12), p=0.342.70±0.792.66±0.770.04 (-0.06–0.14), p=0.41
Reliever inhaler puffs per 24 h2.8±2.92.9±4.42.5±2.73.1±4.4-0.1 (-0.8–0.6), p=0.782.5±2.62.4±2.80.3 (-0.5–1.0), p=0.502.7±2.53.0 [4.0-0.3 (-1.3–0.7), p=0.55
7-point ACQ score1.76±0.881.73±0.741.64±0.901.74±0.850.12 (-0.18–0.42), p=0.431.69 ±1.031.86±0.990.21 (-0.14–0.55), p=0.231.58±0.961.75±0.830.21 (-0.11–0.53), p=0.20
logPC20 mg·mL−10.07±1.140.06±1.41NDNDNDND0.19±1.290.20±1.52-0.02 (-0.49–0.45), p=0.93
Total LCQ score16.90±3.4916.31±3.53NDNDNDND17.51±3.5516.01±3.02-1.06 (-2.16–0.05), p=0.06
Total AQLQ score5.09±0.995.25±1.18NDNDNDND5.42±1.315.20±1.06-0.31 (-0.69–0.07), p=0.11
FeNO50 ppb15.6±21.211.5±8.9NDNDNDND16.2±20.111.0±7.9-1.94 (-5.97–2.10), p=0.34
Total sputum cell count ×104644±240626±245NDNDNDND714±326668±2111.0 (0.9–1.2), p=0.75
Neutrophil ×104150±123172±103NDNDNDND141±96162±9719.2 (-24.2–62.6), p=0.38
Neutrophil %33.1±24.339.0±22.5NDNDNDND31.0±19.934.4±18.63.0 (-5.9–11.8), p=0.50
Eosinophil ×1044.9±6.46.9±9.3NDNDNDND6.8±13.910.3±20.11.0 (0.5–2.0), p=0.89
Eosinophil %1.1±1.51.6±2.3NDNDNDND1.5±3.11.6±3.0-0.4 (-1.8–1.0), p=0.55
  • Data are presented as mean±sd, unless otherwise stated. PEF: peak expiratory flow rate; FEV1: forced expiratory volume in 1 s; ACQ: Asthma Control Questionnaire; PC20: provocation concentration of methacholine causing a 20% fall in FEV1; LCQ: Leicester Cough Questionnaire; AQLQ: Asthma Quality of Life Questionnaire; FeNO50: exhaled nitric oxide fraction at 50 mL·s−1; ND: not done. #: treatment difference from ANCOVA analysing change from baseline and adjusting for baseline value.